

Special Issue

Understanding Non-small Cell Lung Cancer: Biology, Therapeutics and Drug Resistance

Message from the Guest Editors

This Special Issue will seek contributions of research articles and reviews covering a broad spectrum of NSCLC studies, including, but not limited to:

- NSCLC biology: the characterization of novel driver mutations, molecular mediators of transformation and metastasis, metabolic reprogramming and the role of stromal elements within the tumor microenvironment;
- NSCLC biomarkers: the characterization and validation of diagnostic, prognostic and predictive biomarkers;
- NSCLC classification: new approaches for the classification of tumors through the incorporation of genomics, transcriptomics and proteomics. Incorporation of emerging methodologies from the fields of computational biology, machine learning and/or quantitative modeling;
- NSCLC therapeutics: novel approaches to enhance molecular interrogation techniques and promising approaches to overcome resistance using a variety of in silico, in vitro and in vivo models. Advances in research describing chemotherapy, targeted therapy and immunotherapy are also welcome.

Guest Editors

Dr. Mumtaz V. Rojiani

Dr. Ravindra Kolhe

Dr. Pankaj Ahluwalia

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/181618

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).